Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus. - Wikidata - wikimedia - TriplyDB

Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus.

Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus.

http://www.wikidata.org/entity/Q36622125

about

The EMPA-REG outcome study: critical appraisal and potential clinical implications Efficacy and safety of empagliflozin in patients with type 2 diabetes from Asian countries: pooled data from four phase III trials.Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus.Comparison of Adipose Distribution Indices with Gold Standard Body Composition Assessments in the EMPA-REG H2H SU Trial: A Body Composition Sub-Study.A Safety Evaluation of Empagliflozin for the Treatment of Type 2 Diabetes.Impact of empagliflozin in patients with diabetes and heart failure.DPP4 inhibitors and cardiovascular outcomes: safety on heart failure.Cardiovascular safety of therapies for type 2 diabetes.Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus.Differential cardiovascular profiles of sodium-glucose cotransporter 2 inhibitors: critical evaluation of empagliflozin.Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome.Sodium-glucose Cotransporter-2 Inhibitors: Moving Beyond the Glycemic Treatment Goal.Pharmacokinetic drug evaluation of empagliflozin plus linagliptin for the treatment of type 2 diabetes.The heart failure burden of type 2 diabetes mellitus-a review of pathophysiology and interventions.

P2860

Q26748742-BF70B981-1525-4818-BEF7-343C9E695987 Q31105792-B6FB88EC-5683-4901-BAA7-8A3F5F9B377F Q33845734-57048367-20B5-4CBF-9338-A50E74D60397 Q36360090-61449E20-9186-405C-BA4A-87B6D12AD3D5 Q36960633-227F1637-36F6-4462-BC9A-A01C8E3B1D87 Q38822815-BC8D24D9-64F1-43BC-90FC-167D7FF3B738 Q38833312-56BC9026-8D95-4240-8CEC-1A0AF9270EA4 Q38960547-BFD9E5AC-709B-402C-99F4-EF6E7F9B10C9 Q39006105-8A5C4F77-85C0-42AA-BA58-D9C858451F22 Q39300057-8A615086-60A3-43B6-9A55-9103E0E2481F Q41849079-93779D5E-9786-4349-BF77-CB6AA29D5F2E Q47115045-6BD1BCE9-337D-43A5-861A-E6DC254405E5 Q47293312-3D31B0E5-A889-4110-A3EF-C6C845113149 Q55078568-42668A7E-FB9D-4F92-89A4-2E8181ED25DF

P2860

Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus.

http://www.wikidata.org/entity/Q36622125

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Empagliflozin reduces body wei ...... with type 2 diabetes mellitus.

@ast

Empagliflozin reduces body wei ...... with type 2 diabetes mellitus.

@en

type

label

Empagliflozin reduces body wei ...... with type 2 diabetes mellitus.

@ast

Empagliflozin reduces body wei ...... with type 2 diabetes mellitus.

@en

prefLabel

Empagliflozin reduces body wei ...... with type 2 diabetes mellitus.

@ast

Empagliflozin reduces body wei ...... with type 2 diabetes mellitus.

@en

P1433

Q36622125-72F1EDEA-A776-445D-A8CF-23B8BEA0C422

P1476

Q36622125-3755D68E-5912-48D0-B91F-E165F70357A6

P2093

Q36622125-4220E08A-477E-40E6-BBA1-54666D72416A

Q36622125-6B2B287C-E08A-415A-A89F-D0801770428E

Q36622125-6D6F6C62-C446-47C8-9664-A9FFEE636DC4

Q36622125-9232FA99-76FF-476F-AED2-85DA25A48C8C

Q36622125-C270B864-D4BC-4243-A295-528DEE991A0E

Q36622125-D4E56699-BCC5-46A2-919C-5C86F5194218

Q36622125-FCCA13F0-431F-43B7-A665-072034A0D230

P2860

Q36622125-03F56CB6-0A7E-493A-ABFB-173A14FB4F4C

Q36622125-15A066FF-0BEA-4008-98CB-84614D466514

Q36622125-17A31F76-D135-4F33-9197-8B3520149A6C

Q36622125-1AE7A33F-403E-4874-AA13-2688324C78E3

Q36622125-56DBE0DC-1A24-4094-87C4-66288CE55AF3

Q36622125-6305A82D-5660-4F69-B01C-6D3D0971CBDC

Q36622125-6694CF78-36EB-4EE4-B9D9-DC7A6B20CECE

Q36622125-70358AA9-27E7-497A-AC8B-E6E34009C302

Q36622125-77086986-877F-4010-B4EA-C89F01E7A3F1

Q36622125-7C54F5AA-71C3-4C83-BCE2-804408793142

P304

Q36622125-342D80A9-8B04-4D03-AC6C-771290545C77

P31

Q36622125-1C23569D-E228-4ED7-814C-66213387181C

P356

Q36622125-BC501006-5484-493A-A4F6-4F3CA1478980

P407

Q36622125-268F5982-D991-4228-84FA-CCE2C53793BB

P433

Q36622125-5742138C-5D31-4632-85CE-307784F81E46

P478

Q36622125-ACFE9A82-10DB-4843-A017-FB2A323515A4

P50

Q36622125-13C5C35D-750D-451D-9A8D-7C6C50E270CF

P577

Q36622125-84D3877C-5BC5-47E6-853F-4A3580B0EC41

P5875

Q36622125-82654A30-5A08-4656-81BD-B7BC69A062A1

P698

Q36622125-9C7D2EFC-4663-4236-A399-D8003582E264

P921

Q36622125-CBF2F465-2960-4BA9-BF93-B1FAE31095D8

P932

Q36622125-EE46E0F0-EAF0-42C3-8E90-FBBF325C05A1

P356

1479164115616901

P1433

Diabetes and Vascular Disease Research

P1476

Empagliflozin reduces body wei ...... with type 2 diabetes mellitus.

@en

P2093

Darren K McGuire

http://www.w3.org/2001/XMLSchema#string

Hans J Woerle

http://www.w3.org/2001/XMLSchema#string

Ian J Neeland

http://www.w3.org/2001/XMLSchema#string

Robert Chilton

http://www.w3.org/2001/XMLSchema#string

Susanne Crowe

http://www.w3.org/2001/XMLSchema#string

Søren S Lund

http://www.w3.org/2001/XMLSchema#string

Uli C Broedl

http://www.w3.org/2001/XMLSchema#string

P2860

Visceral Adiposity Index: a reliable indicator of visceral fat function associated with cardiometabolic risk.

Index of central obesity - A novel parameter.

Changing definitions of metabolic syndrome.

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Index of central obesity is better than waist circumference in defining metabolic syndrome.

SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials.

Bariatric surgery versus intensive medical therapy in obese patients with diabetes.

Comparison of Adipose Distribution Indices with Gold Standard Body Composition Assessments in the EMPA-REG H2H SU Trial: A Body Composition Sub-Study.

Factors associated with percent change in visceral versus subcutaneous abdominal fat during weight loss: findings from a systematic review.

Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk.

P304

119-126

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1479164115616901

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

Odd Erik Johansen

P577

2016-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

288888122

http://www.w3.org/2001/XMLSchema#string

P698

26873905

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

4768401

http://www.w3.org/2001/XMLSchema#string